{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T16:30:35Z","timestamp":1784565035494,"version":"3.55.0"},"reference-count":78,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:00:00Z","timestamp":1707523200000},"content-version":"am","delay-in-days":315,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["5R01DA040811-03"],"award-info":[{"award-number":["5R01DA040811-03"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jsatjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Substance Use and Addiction Treatment"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.josat.2023.208973","type":"journal-article","created":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T21:46:15Z","timestamp":1675979175000},"page":"208973","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Trajectories of non\u2013prescribed buprenorphine and other opioid use: A multi-trajectory latent class growth analysis"],"prefix":"10.1016","volume":"147","author":[{"given":"Raminta","family":"Daniulaityte","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramzi W.","family":"Nahhas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sydney","family":"Silverstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Martins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert G.","family":"Carlson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.josat.2023.208973_bb0005","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13722-021-00244-8","article-title":"Initiating buprenorphine to treat opioid use disorder without prerequisite withdrawal: A systematic review","volume":"16","author":"Adams","year":"2021","journal-title":"Addiction Science & Clinical Practice"},{"key":"10.1016\/j.josat.2023.208973_bb0010","series-title":"Provisional drug overdose death counts","author":"Ahmad","year":"2021"},{"key":"10.1016\/j.josat.2023.208973_bb0015","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jsat.2016.08.002","article-title":"Non-prescribed buprenorphine in New York City: Motivations for use, practices of diversion, and experiences of stigma","volume":"70","author":"Allen","year":"2016","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"4","key":"10.1016\/j.josat.2023.208973_bb9000","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1370\/afm.2099","article-title":"Barriers rural physicians face prescribing buprenorphine for opioid use disorder","volume":"15","author":"Andrilla","year":"2017","journal-title":"Annals of Family Medicine"},{"issue":"11","key":"10.1016\/j.josat.2023.208973_bb0020","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1111\/add.13491","article-title":"Non-medical use of prescription opioids is associated with heroin initiation among US veterans: A prospective cohort study","volume":"111","author":"Banerjee","year":"2016","journal-title":"Addiction"},{"issue":"3","key":"10.1016\/j.josat.2023.208973_bb0025","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/ADM.0b013e3182034e31","article-title":"Illicit use of buprenorphine\/naloxone among injecting and noninjecting opioid users","volume":"5","author":"Bazazi","year":"2011","journal-title":"Journal of Addiction Medicine"},{"issue":"1","key":"10.1016\/j.josat.2023.208973_bb0030","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13722-017-0072-2","article-title":"Public sector low threshold office-based buprenorphine treatment: Outcomes at year 7","volume":"12","author":"Bhatraju","year":"2017","journal-title":"Addiction Science & Clinical Practice"},{"issue":"10","key":"10.1016\/j.josat.2023.208973_bb0035","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0030452","article-title":"Reinterpreting ethnic patterns among white and African American men who inject heroin: A social science of medicine approach","volume":"3","author":"Bourgois","year":"2006","journal-title":"PLoS Medicine"},{"issue":"1","key":"10.1016\/j.josat.2023.208973_bb0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/002204261004000101","article-title":"Introduction to the special issue on \"Statistical approaches and methodological issues in longitudinal analysis of substance use and related behaviors\"","volume":"40","author":"Brecht","year":"2010","journal-title":"Journal of Drug Issues"},{"issue":"11","key":"10.1016\/j.josat.2023.208973_bb0045","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1002\/pds.5334","article-title":"Increasing rates of buprenorphine diversion in the United States, 2002 to 2019","volume":"30","author":"Buttram","year":"2021","journal-title":"Pharmacoepidemiology and Drug Safety"},{"key":"10.1016\/j.josat.2023.208973_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2020.102722","article-title":"Unintentional drug overdose: Is more frequent use of non-prescribed buprenorphine associated with lower risk of overdose?","volume":"79","author":"Carlson","year":"2020","journal-title":"International Journal on Drug Policy"},{"key":"10.1016\/j.josat.2023.208973_bb0055","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.drugalcdep.2015.12.026","article-title":"Predictors of transition to heroin use among initially non-opioid dependent illicit pharmaceutical opioid users: A natural history study","volume":"160","author":"Carlson","year":"2016","journal-title":"Drug and Alcohol Dependence."},{"issue":"6","key":"10.1016\/j.josat.2023.208973_bb0060","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1097\/ADM.0000000000000436","article-title":"The more things change: Buprenorphine\/naloxone diversion continues while treatment remains inaccessible","volume":"12","author":"Carroll","year":"2018","journal-title":"Journal of Addiction Medicine"},{"issue":"3","key":"10.1016\/j.josat.2023.208973_bb0065","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.jpeds.2015.04.071","article-title":"Nonmedical prescription opioid use in childhood and early adolescence predicts transitions to heroin use in young adulthood: A national study","volume":"167","author":"Cerda","year":"2015","journal-title":"Journal of Pediatrics"},{"key":"10.1016\/j.josat.2023.208973_bb0070","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jsat.2019.07.005","article-title":"Buprenorphine in the United States: Motives for abuse, misuse, and diversion","volume":"104","author":"Chilcoat","year":"2019","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.josat.2023.208973_bb0075","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.drugalcdep.2018.09.007","article-title":"Understanding the use of diverted buprenorphine","volume":"193","author":"Cicero","year":"2018","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.josat.2023.208973_bb0080","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.drugalcdep.2014.06.005","article-title":"Factors contributing to the rise of buprenorphine misuse: 2008\u20132013","volume":"142","author":"Cicero","year":"2014","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.josat.2023.208973_bb0085","series-title":"State variation in medicaid prescriptions for opioid use disorder from 2011 to 2018","author":"Clemans-Cope","year":"2019"},{"issue":"4","key":"10.1016\/j.josat.2023.208973_bb0090","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/ADM.0b013e31829727b2","article-title":"Prior buprenorphine experience is associated with office-based buprenorphine treatment outcomes","volume":"7","author":"Cunningham","year":"2013","journal-title":"Journal of Addiction Medicine"},{"issue":"6","key":"10.1016\/j.josat.2023.208973_bb0095","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1007\/s11606-017-3993-2","article-title":"Emergency department-initiated buprenorphine for opioid dependence with continuation in primary care: Outcomes during and after intervention","volume":"32","author":"D'Onofrio","year":"2017","journal-title":"Journal of General Internal Medicine"},{"issue":"5","key":"10.1016\/j.josat.2023.208973_bb0100","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/ajad.12213","article-title":"\"Sub is a weird drug:\" a web-based study of lay attitudes about use of buprenorphine to self-treat opioid withdrawal symptoms","volume":"24","author":"Daniulaityte","year":"2015","journal-title":"American Journal on Addictions"},{"key":"10.1016\/j.josat.2023.208973_bb0105","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.drugpo.2019.05.020","article-title":"Street fentanyl use: Experiences, preferences, and concordance between self-reports and urine toxicology","volume":"71","author":"Daniulaityte","year":"2019","journal-title":"International Journal on Drug Policy"},{"issue":"3","key":"10.1016\/j.josat.2023.208973_bb0110","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.drugalcdep.2011.09.029","article-title":"Illicit use of buprenorphine in a community sample of young adult non-medical users of pharmaceutical opioids","volume":"122","author":"Daniulaityte","year":"2012","journal-title":"Drug and Alcohol Dependence"},{"issue":"1\u20132","key":"10.1016\/j.josat.2023.208973_bb0115","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.drugalcdep.2011.08.005","article-title":"Respondent-driven sampling to recruit young adult non-medical users of pharmaceutical opioids: Problems and solutions","volume":"121","author":"Daniulaityte","year":"2012","journal-title":"Drug and Alcohol Dependence"},{"issue":"8","key":"10.1016\/j.josat.2023.208973_bb0120","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.addbeh.2009.03.037","article-title":"Illicit use of pharmaceutical opioids among young polydrug users in Ohio","volume":"34","author":"Daniulaityte","year":"2009","journal-title":"Addictive Behaviors"},{"key":"10.1016\/j.josat.2023.208973_bb0125","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.drugalcdep.2019.01.045","article-title":"Trends in fentanyl and fentanyl analogue-related overdose deaths - Montgomery County, Ohio, 2015\u20132017","volume":"198","author":"Daniulaityte","year":"2019","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.josat.2023.208973_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2019.107574","article-title":"Patterns of non-prescribed buprenorphine and other opioid use among individuals with opioid use disorder: A latent class analysis","volume":"204","author":"Daniulaityte","year":"2019","journal-title":"Drug and Alcohol Dependence"},{"issue":"4","key":"10.1016\/j.josat.2023.208973_bb0135","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1111\/j.1360-0443.2011.03473.x","article-title":"Primary outcome indices in illicit drug dependence treatment research: Systematic approach to selection and measurement of drug use end-points in clinical trials","volume":"107","author":"Donovan","year":"2012","journal-title":"Addiction (Abingdon, England)"},{"issue":"8","key":"10.1016\/j.josat.2023.208973_bb0140","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1111\/add.14620","article-title":"Criminal justice outcomes over 5 years after randomization to buprenorphine-naloxone or methadone treatment for opioid use disorder","volume":"114","author":"Evans","year":"2019","journal-title":"Addiction"},{"issue":"1","key":"10.1016\/j.josat.2023.208973_bb0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jsat.2004.03.012","article-title":"Selection of a substance use disorder diagnostic instrument by the National Drug Abuse Treatment Clinical Trials Network","volume":"27","author":"Forman","year":"2004","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.josat.2023.208973_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2019.06.029","article-title":"U.S. Trends in the supply of providers with a waiver to prescribe buprenorphine for opioid use disorder in 2016 and 2018","volume":"204","author":"Ghertner","year":"2019","journal-title":"Drug and Alcohol Dependence"},{"issue":"9","key":"10.1016\/j.josat.2023.208973_bb0155","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1176\/appi.ps.201900635","article-title":"Increases in providers with buprenorphine waivers in the United States from 2016 to 2019","volume":"71","author":"Ghertner","year":"2020","journal-title":"Psychiatric Services"},{"key":"10.1016\/j.josat.2023.208973_bb0160","series-title":"U.S. Department of Health and Human Services Overdose Prevention Strategy","author":"Haffajee","year":"2021"},{"issue":"8","key":"10.1016\/j.josat.2023.208973_bb0165","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1080\/10826084.2021.1908360","article-title":"\"The doctor says you cannot have [Buprenorphine]\" autonomy and use of prescribed or non-prescribed buprenorphine","volume":"56","author":"Hayes","year":"2021","journal-title":"Substance Use and Misuse"},{"key":"10.1016\/j.josat.2023.208973_bb0170","doi-asserted-by":"crossref","first-page":"174","DOI":"10.2307\/3096941","article-title":"Respondent-driven sampling: A new approach to the study of hidden population","volume":"44","author":"Heckathorn","year":"1997","journal-title":"Social Problems"},{"issue":"1","key":"10.1016\/j.josat.2023.208973_bb0175","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/ADM.0000000000000274","article-title":"Distinctive trajectories of opioid use over an extended follow-up of patients in a multisite trial on buprenorphine + naloxone and methadone","volume":"11","author":"Hser","year":"2017","journal-title":"Journal of Addiction Medicine"},{"issue":"2","key":"10.1016\/j.josat.2023.208973_bb0180","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/ADM.0000000000000555","article-title":"Defining low-threshold buprenorphine treatment","volume":"14","author":"Jakubowski","year":"2020","journal-title":"Journal of Addiction Medicine"},{"issue":"4","key":"10.1016\/j.josat.2023.208973_bb0185","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1097\/ADM.0000000000000934","article-title":"Low-threshold buprenorphine treatment in a syringe services program: Program description and outcomes","volume":"16","author":"Jakubowski","year":"2022","journal-title":"Journal of Addiction Medicine"},{"key":"10.1016\/j.josat.2023.208973_bb0190","series-title":"Behavioural surveillance: Introduction to respondent driven sampling (participant manual)","author":"Johnston","year":"2008"},{"issue":"8","key":"10.1016\/j.josat.2023.208973_bb0195","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.2105\/AJPH.2015.302664","article-title":"National and state treatment need and capacity for opioid agonist medication-assisted treatment","volume":"105","author":"Jones","year":"2015","journal-title":"American Journal of Public Health"},{"issue":"3","key":"10.1016\/j.josat.2023.208973_bb0200","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1080\/08897077.2021.1975344","article-title":"Research priorities for expanding access to methadone treatment for opioid use disorder in the United States: A National Institute on Drug Abuse Center for clinical trials network task force report","volume":"42","author":"Joudrey","year":"2021","journal-title":"Substance Abuse"},{"key":"10.1016\/j.josat.2023.208973_bb0205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jsat.2019.05.002","article-title":"Expanding low-threshold buprenorphine to justice-involved individuals through mobile treatment: Addressing a critical care gap","volume":"103","author":"Krawczyk","year":"2019","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"1","key":"10.1016\/j.josat.2023.208973_bb0210","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/10705511.2013.742377","article-title":"Latent class analysis with distal outcomes: A flexible model-based approach","volume":"20","author":"Lanza","year":"2013","journal-title":"Structural Equation Modeling : A Multidisciplinary Journal"},{"issue":"2","key":"10.1016\/j.josat.2023.208973_bb0215","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.36687","article-title":"Systematic evaluation of state policy interventions targeting the US opioid epidemic, 2007\u20132018","volume":"4","author":"Lee","year":"2021","journal-title":"JAMA Network Open"},{"issue":"14","key":"10.1016\/j.josat.2023.208973_bb0220","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1080\/10826084.2021.1975749","article-title":"Intervention stigma toward medications for opioid use disorder: A systematic review","volume":"56","author":"Madden","year":"2021","journal-title":"Substance Use and Misuse"},{"key":"10.1016\/j.josat.2023.208973_bb0225","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.drugalcdep.2015.03.020","article-title":"Racial\/ethnic differences in trends in heroin use and heroin-related risk behaviors among nonmedical prescription opioid users","volume":"151","author":"Martins","year":"2015","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.josat.2023.208973_bb0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2021.108978","article-title":"Gender differences in the prevalence of heroin and opioid analgesic misuse in the United States, 2015\u20132019","volume":"227","author":"McHugh","year":"2021","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.josat.2023.208973_bb0235","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.drugpo.2019.06.019","article-title":"\"They're making it so hard for people to get help:\" motivations for non-prescribed buprenorphine use in a time of treatment expansion","volume":"71","author":"McLean","year":"2019","journal-title":"International Journal on Drug Policy"},{"issue":"3","key":"10.1016\/j.josat.2023.208973_bb0240","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1080\/02791072.2019.1566583","article-title":"Barriers to buprenorphine expansion in Ohio: A time-elapsed qualitative study","volume":"51","author":"Molfenter","year":"2019","journal-title":"Journal of Psychoactive Drugs"},{"key":"10.1016\/j.josat.2023.208973_bb0245","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jsat.2015.04.010","article-title":"Prior experience with non-prescribed buprenorphine: Role in treatment entry and retention","volume":"57","author":"Monico","year":"2015","journal-title":"Journal of Substance Abuse Treatment."},{"issue":"3","key":"10.1016\/j.josat.2023.208973_bb0250","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1080\/10550880903014767","article-title":"Diversion of buprenorphine\/naloxone coformulated tablets in a region with high prescribing prevalence","volume":"28","author":"Monte","year":"2009","journal-title":"Journal of Addictive Diseases"},{"key":"10.1016\/j.josat.2023.208973_bb0255","article-title":"Potential barriers to filling buprenorphine and naltrexone prescriptions among a retrospective cohort of individuals with opioid use disorder","volume":"108540","author":"Morgan","year":"2021","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.josat.2023.208973_bb0260","series-title":"Mplus user's guide","author":"Muth\u00e9n","year":"2017"},{"issue":"7","key":"10.1016\/j.josat.2023.208973_bb0265","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1177\/0962280216673085","article-title":"Group-based multi-trajectory modeling","volume":"27","author":"Nagin","year":"2018","journal-title":"Statistical Methods in Medical Research"},{"issue":"1","key":"10.1016\/j.josat.2023.208973_bb0270","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1037\/1082-989X.6.1.18","article-title":"Analyzing developmental trajectories of distinct but related behaviors: A group-based method","volume":"6","author":"Nagin","year":"2001","journal-title":"Psychological Methods"},{"issue":"5","key":"10.1016\/j.josat.2023.208973_bb0275","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1007\/s10461-017-1790-x","article-title":"Using a \"positive deviance\" framework to discover adaptive risk reduction behaviors among high-risk HIV negative black men who have sex with men","volume":"22","author":"Ober","year":"2018","journal-title":"AIDS and Behavior"},{"issue":"3","key":"10.1016\/j.josat.2023.208973_bb0280","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1001\/jama.2019.18913","article-title":"Trends in buprenorphine treatment in the United States, 2009\u20132018","volume":"323","author":"Olfson","year":"2020","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.josat.2023.208973_bb8000","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1177\/1073110520935353","article-title":"Decriminalization of diverted buprenorphine in Burlington, Vermont and Philadelphia: An intervention to reduce opioid overdose deaths","volume":"48","author":"Pozo","year":"2020","journal-title":"The Journal of Law, Medicine & Ethics : A Journal of the American Society of Law, Medicine & Ethics"},{"issue":"3","key":"10.1016\/j.josat.2023.208973_bb0285","doi-asserted-by":"crossref","DOI":"10.1503\/cmaj.74018","article-title":"Buprenorphine-naloxone \"microdosing\": an alternative induction approach for the treatment of opioid use disorder in the wake of North America's increasingly potent illicit drug market","volume":"192","author":"Randhawa","year":"2020","journal-title":"CMAJ: Canadian Medical Association Journal"},{"key":"10.1016\/j.josat.2023.208973_bb0290","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2021.108405","article-title":"Buprenorphine use and disparities in access among emergency department patients with opioid use disorder: A cross-sectional study","volume":"130","author":"Robbins","year":"2021","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.josat.2023.208973_bb0295","series-title":"Diagnostic interview schedule for DSM-IV","author":"Robins","year":"2002"},{"issue":"1","key":"10.1016\/j.josat.2023.208973_bb0300","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1037\/a0030992","article-title":"Reliability of the timeline followback for cocaine, cannabis, and cigarette use","volume":"28","author":"Robinson","year":"2014","journal-title":"Psychology of addictive behaviors : journal of the Society of Psychologists in Addictive Behaviors"},{"issue":"447","key":"10.1016\/j.josat.2023.208973_bb0305","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1080\/01621459.1999.10474179","article-title":"Modeling uncertainty in latent class membership: A case study in criminology","volume":"94","author":"Roeder","year":"1999","journal-title":"Journal of the American Statistical Association"},{"key":"10.1016\/j.josat.2023.208973_bb0310","series-title":"Multiple imputation for nonresponse in surveys","author":"Rubin","year":"1987"},{"issue":"2","key":"10.1016\/j.josat.2023.208973_bb0315","doi-asserted-by":"crossref","first-page":"284","DOI":"10.2105\/AJPH.2021.306577","article-title":"Self-reported treatment need and barriers to care for adults with opioid use disorder: The US National Survey on drug use and health, 2015 to 2019","volume":"112","author":"Saini","year":"2022","journal-title":"American Journal of Public Health"},{"issue":"5","key":"10.1016\/j.josat.2023.208973_bb0320","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1377\/hlthaff.2019.01085","article-title":"Impact of long-term buprenorphine treatment on adverse health care outcomes in medicaid","volume":"39","author":"Samples","year":"2020","journal-title":"Health Affairs"},{"key":"10.1016\/j.josat.2023.208973_bb0325","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jsat.2018.09.001","article-title":"Risk factors for discontinuation of buprenorphine treatment for opioid use disorders in a multi-state sample of medicaid enrollees","volume":"95","author":"Samples","year":"2018","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"1","key":"10.1016\/j.josat.2023.208973_bb0330","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jsat.2010.03.014","article-title":"Self-treatment: Illicit buprenorphine use by opioid-dependent treatment seekers","volume":"39","author":"Schuman-Olivier","year":"2010","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.josat.2023.208973_bb0335","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.drugpo.2019.09.003","article-title":"\"Everything is not right anymore\": Buprenorphine experiences in an era of illicit fentanyl","volume":"74","author":"Silverstein","year":"2019","journal-title":"International Journal on Drug Policy"},{"key":"10.1016\/j.josat.2023.208973_bb0340","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2020.107958","article-title":"On my own terms: Motivations for self-treating opioid-use disorder with non-prescribed buprenorphine","volume":"210","author":"Silverstein","year":"2020","journal-title":"Drug and Alcohol Dependence"},{"issue":"S2","key":"10.1016\/j.josat.2023.208973_bb0345","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.2105\/AJPH.2021.306665","article-title":"The methadone manifesto: Treatment experiences and policy recommendations from methadone patient activists","volume":"112","author":"Simon","year":"2022","journal-title":"American Journal of Public Health"},{"issue":"1","key":"10.1016\/j.josat.2023.208973_bb0350","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1081\/JA-120027764","article-title":"Gender and other factors associated with the nonmedical use of abusable prescription drugs","volume":"39","author":"Simoni-Wastila","year":"2004","journal-title":"Substance Use and Misuse"},{"key":"10.1016\/j.josat.2023.208973_bb0355","series-title":"Measuring alcohol consumption: Psychosocial and biological methods","first-page":"41","article-title":"Timeline follow-back: A technique for assessing self-reported alcohol consumption","author":"Sobell","year":"1992"},{"key":"10.1016\/j.josat.2023.208973_bb0360","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2020.108176","article-title":"It's not just the money: The role of treatment ideology in publicly funded substance use disorder treatment","volume":"120","author":"Stewart","year":"2021","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"4","key":"10.1016\/j.josat.2023.208973_bb0365","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1097\/ADM.0000000000000952","article-title":"A plea from people who use drugs to clinicians: New ways to initiate buprenorphine are urgently needed in the fentanyl era","volume":"16","author":"Sue","year":"2022","journal-title":"Journal of Addiction Medicine"},{"issue":"3","key":"10.1016\/j.josat.2023.208973_bb0370","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1177\/00220426221076800","article-title":"Medications for opioid use disorder in the criminal\/legal system: Knowledge, beliefs, and attitudes among rural community-based stakeholders","volume":"52","author":"Victor","year":"2022","journal-title":"Journal of Drug Issues"},{"key":"10.1016\/j.josat.2023.208973_bb0375","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.drugalcdep.2016.10.015","article-title":"Treatment utilization among persons with opioid use disorder in the United States","volume":"169","author":"Wu","year":"2016","journal-title":"Drug and Alcohol Dependence"},{"issue":"1","key":"10.1016\/j.josat.2023.208973_bb0380","doi-asserted-by":"crossref","first-page":"28","DOI":"10.2174\/1874473711104010028","article-title":"Buprenorphine and buprenorphine\/naloxone diversion, misuse, and illicit use: An international review","volume":"4","author":"Yokell","year":"2011","journal-title":"Current Drug Abuse Reviews"}],"container-title":["Journal of Substance Use and Addiction Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949875923000231?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949875923000231?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T15:48:57Z","timestamp":1757432937000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949875923000231"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":78,"alternative-id":["S2949875923000231"],"URL":"https:\/\/doi.org\/10.1016\/j.josat.2023.208973","relation":{},"ISSN":["2949-8759"],"issn-type":[{"value":"2949-8759","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Trajectories of non\u2013prescribed buprenorphine and other opioid use: A multi-trajectory latent class growth analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Substance Use and Addiction Treatment","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.josat.2023.208973","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"208973"}}